Intech Investment Management LLC Invests $91,000 in Sutro Biopharma, Inc. (NASDAQ:STRO)

Intech Investment Management LLC acquired a new stake in Sutro Biopharma, Inc. (NASDAQ:STRO) in the 3rd quarter, Holdings Channel reports. The firm acquired 26,336 shares of the company’s stock, valued at approximately $91,000.

Several other large investors also recently bought and sold shares of STRO. Vanguard Group Inc. grew its position in shares of Sutro Biopharma by 4.6% in the first quarter. Vanguard Group Inc. now owns 3,022,790 shares of the company’s stock valued at $17,079,000 after purchasing an additional 132,790 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Sutro Biopharma by 24.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 18,027 shares of the company’s stock valued at $102,000 after acquiring an additional 3,578 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Sutro Biopharma by 47.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 272,719 shares of the company’s stock valued at $799,000 after buying an additional 88,034 shares during the period. Panagora Asset Management Inc. increased its holdings in shares of Sutro Biopharma by 15.6% during the 2nd quarter. Panagora Asset Management Inc. now owns 907,503 shares of the company’s stock worth $2,659,000 after buying an additional 122,299 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in Sutro Biopharma by 23.3% in the second quarter. Rhumbline Advisers now owns 116,099 shares of the company’s stock valued at $340,000 after acquiring an additional 21,935 shares during the last quarter. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma Stock Up 2.2 %

Shares of NASDAQ:STRO opened at $2.84 on Monday. The company’s 50-day moving average price is $3.37 and its 200 day moving average price is $3.67. The company has a market cap of $234.19 million, a PE ratio of -1.76 and a beta of 1.09. Sutro Biopharma, Inc. has a fifty-two week low of $2.45 and a fifty-two week high of $6.13.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on STRO shares. JMP Securities reaffirmed a “market outperform” rating and issued a $17.00 target price on shares of Sutro Biopharma in a research report on Monday, September 16th. Truist Financial reduced their price objective on shares of Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, August 16th. Piper Sandler reissued an “overweight” rating and issued a $11.00 price objective on shares of Sutro Biopharma in a report on Friday, October 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Sutro Biopharma in a report on Monday, November 18th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $12.14.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.